⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VNDA News
Vanda Pharmaceuticals Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
accessnewswire.com
VNDA
Vanda and Exante Data Combine in Strategic Merger
businesswire.com
VNDA
Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder
prnewswire.com
VNDA
Global Sleep Tech Devices Market Poised for Strong Growth at a CAGR of ~17% by 2032, Driven by Rising Sleep Disorder Prevalence | DelveInsight
globenewswire.com
RMD
AXSM
JAZZ
AVDL
LLY
VNDA
Bipolar Disorder Market Opportunity Assessment and Forecast Report 2024-2034: Addressing Treatment Gaps in Bipolar Depression, Early Diagnosis, Patient Adherence, and Clinical Trial Effectiveness - ResearchAndMarkets.com
businesswire.com
BMY
VNDA
XENE
Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness
prnewswire.com
VNDA
Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
prnewswire.com
VNDA
ANAB
Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
globenewswire.com
AMGN
PFE
LLY
AZN
BMY
NVS
SNY
GSK
UCB
ARQT
REGN
INCY
ABBV
BIIB
MRK
JNJ
VNDA
RAPT
CHAI
ONON
ION
ASMB
CRVS
APG
KSCP
KYMR
XBI
IBB
ADSK
CDNS
SNPS
FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness
prnewswire.com
VNDA
Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness
prnewswire.com
VNDA